BioXpedia A/S is a contract research laboratory founded in 2016 by CEO Mogens Kruhøffer to provide high quality cost effective targeted biomarker screening to pre-clinical and clinical researchers. Our main focus is on the identification of new clinically useful biomarkers for patient stratification, treatment response, and discovery of potential drug targets.
BioXpedia provides high-throughput sample preparation and multiomic screening and analyses on multiple biological levels. We offer you the rapid high-throughput analysis that your research deserves, using multiplex low-volume technologies for the most effective use of your valuable samples.
Since its foundation, BioXpedia has helped clients from the pharmaceutical and biotech industry along with research groups and other larger research institution with a variety of projects involving biomarker services. We are passionate about being your trusted scientific partner in biomarker discovery and validation.
Use our services to advance your research, diagnostic and drug development projects.
NB BioXpedia wil not claim any intellectual property rights (IPR) of data and results generated.
Head of Board
Brian holds a Master of Law from Aarhus University. He has more than 12 years of business experience as manager in businesses. Brian has amongst others held various non-legal management positions in LEGO, been the CEO of an American franchisor company and of AROS Applied Biotechnology. In 2013 Brian joined Marselis Advokater as Partner, where he works with the application and enforcement of intellectual property rights. Brian has performed legal work for a wide range of large and midsized businesses in Denmark and abroad.
Board memberNiels holds an MSc in chemistry and a PhD in molecular biology. He previously worked for 18 years on characterizing genetic diseases and founded a University Hospital Laboratory dedicated to the diagnosis of inherited diseases. He is a renowned teacher of molecular biology techniques, including PCR, real time PCR and array technologies to students up to PhD level. In 2001 Niels joined AH diagnostics as managing director and is now the main shareholder of the company.
Board member CEO
Mogens holds an MSc in biology from Aarhus University and a Ph.D. in molecular biology from the Max-Planck-Institute for Experimental Medicine. He was the cofounder of AROS Applied Biotechnology back in 2000 and worked as CSO up until 2017, where he left the company to start BioXpedia. Mogens has previously worked extensively with genome analysis and has a long research career behind him.
Contact info: firstname.lastname@example.org, mobile +45 28 19 26 82
Project ManagerContact info: email@example.com
Cell: +45 28 19 96 90
Head Laboratory Technician
Contact info: firstname.lastname@example.org
Data ScientistContact info: email@example.com
Product SpecialistContact info: firstname.lastname@example.org
Cell: +45 24 84 84 85
What scientists are saying about BioXpedia
”It is great that a professional provider will ensure the quality in these new and competence demanding analyses. Mogens has many years of experience from collaborations with the pharmaceutical industry under GLP-demands, and I am sure that this is a guarantee of competences and quality.”Torben F. Ørntoft,
”During my Ph.D project my supervisor drew my attention to BioXpedia’s services. Especially interesting for me was the biomarker screening using the Olink Proteomics platform, and I quickly realized it could benefit my research substantially by enabling a more comprehensive analysis of my samples. The panels available did not include assays for all the biomarkers I wanted to analyze, however, the BioXpedia team quickly found a solution allowing for a complete analysis of all biomarkers – and they thoroughly instructed me in the sample preparation process. I have experienced a very positive cooperation with a high degree of kindness, professionalism and flexibility, and I look forward to my future cooperation with the BioXpedia team.”Mia Klinkvort Kempel,
”We are used to measuring 1-2 relations at a time, while this type of panels make it possible to broaden the analysis, so that we at one time fast and precisely may measure the content of several substances and proteins in a biopsy. If this screening method holds its promise, it is fantastic. It might turn out to be of huge importance to guiding us and giving an overview of the identification process to find disease markers.”Kristian Stengaard-Pedersen
”Immunotherapy is currently a popular and effective method for treating lung cancer. Unfortunately, it can be difficult to follow the effect of the treatment, especially in the beginning, where the tumour progression cannot be monitored using x-ray as with traditional chemotherapy and radiation therapy. Thus, we are searching for valid and suitable clinical biomarkers, that will allow us to non-invasively monitor the effect of the treatment i.e. in blood and bronchial secretions. These new protein screening panels have an enormous potential, as targeted biomarker analysis will enable us to perform broad analyses of immune proteins and monitor how the treatment affects their up and down regulation.”Henrik Hager,
“BioXpedia has been dedicated to help me achieve my research goals and move forward. The staff are friendly, competent, efficient and eager to make sure that all flows smoothly to obtain the best possible solution and results. I would strongly recommend to anybody wanting to have quality results, delivered with care and precision.”Meg Duroux,
Come meet us
22 March 2018, Skejby